Benazepril position in the modern treatment of arterial hypertension Review article
Article Sidebar
Published:
Dec 31, 2011
Keywords:
arterial hypertension, angiotensin-converting enzyme inhibitors, benazepril
Main Article Content
Abstract
The current guidelines on arterial hypertension management highlighted the role of global cardiovascular risk assessment of the individual patient. This evaluation should influence the decision about starting pharmacotherapy. For the majority of patients, including patients with concomitant diseases or high cardiovascular risk, angiotensin-converting inhibitors may represent the most appropriate choice. Benazepril which is a representative of this group is a drug of proven antihypertensive efficacy, favorable influence on subclinical organ complications and cardiovascular prognosis, making it a good choice in both mono- and polytherapy of hypertension.
Article Details
How to Cite
Grabysa , R. (2011). Benazepril position in the modern treatment of arterial hypertension. Medycyna Faktow (J EBM), 4(4(13), 87-92. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2508
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Mathers C., Stevens G., Mascarenas M.: Global health risks: mortality and burden of disease attributable to selected major risks. Geneva, Switzerland: World Health Organization, 2009. [online].
2. Kearney P.M., Whelton M., Reynolds K. et al.: Worldwide prevalence of hypertension: a systematic review. J. Hypertens. 2004; 22: 11-19.
3. Wolf-Maier K., Cooper R.S., Banegas J.R. et al.: Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA 2003; 289: 2363-2369.
4. Strasser T.: Hypertension: the East European experience. Am. J. Hypertens. 1998; 11: 756-758.
5. Zdrojewski T., Bandosz P., Szpakowski P. et al.: Rozpowszechnienie głównych czynników ryzyka chorób układu sercowo-naczyniowego w Polsce. Wyniki badania NATPOL PLUS. Kardiol. Pol. 2004; 61(supl. 4): S1-S26.
6. Tykarski A., Posadzy-Małaczyńska A., Wyrzykowski B. et al.: Rozpowszechnienie nadciśnienia tętniczego oraz skuteczność jego leczenia u dorosłych mieszkańców naszego kraju. Wyniki programu WOBASZ. Kardiol. Pol. 2005; 63: S614-S619.
7. Mancia G., De Backer G., Dominiczak A. et al.: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Hypertension (ESH). J. Hypertens. 2007; 25: 1105-87.
8. Mancia G., Laurent S., Agabiti-Rosei E. et al.: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 2009; 27: 2121-58.
9. Widecka K., Grodzicki T., Narkiewicz K. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2011 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze 2011; 15: 55-82.
10. Kasprzak J.D.: Optymalna kontrola ciśnienia tętniczego u pacjentów z grupy wysokiego ryzyka krążeniowego: pozycja perindoprilu. Choroby Serca i Naczyń 2011; 2: 53-61.
11. Opie L.H.: Inhibitory konwertazy angiotensyny. Postęp trwa. Via Medica, Gdańsk 2000.
12. Schaller M., Nussberger J., Waeber B. et al.: Haemodynamic and pharmacological effects of the converting enzyme inhibitor benazepril HCl in normal volunteers. Eur. J. Clin. Pharmacol. 1985; 28: 267-272.
13. Johnston C.I., Mendelsohn F.A.O., Cubela R.B. et al.: Inhibition of angiotensin converting enzyme (ACE) in plasma and tissues: studies ex vivo after administration of ACE inhibitors. J. Hypertens. 1988; 6(supl. 3): S17-S22.
14. Smith W.M., Gomez H.J.: The use of benazepril in hypertensive patients age 55 and over. Clin. Cardiol. 1991; 14: 79-90.
15. Bellet M., Whalen J.J., Bodin F. et al.: Use of crossover trials to obtain antihypertensive dose-response curves and to study combination therapy during the development of benazepril. J. Hypertens. 1990; 8: 43-48.
16. Fogari R., Zoppi A., Lusardi P. et al.: Effects of benazepril alone and in combination with hydrochlorothiazide in comparison with felodypine extended release in elderly patients with mild-to-moderate essential hypertension. Curr. Therap. Res. 1998; 59: 246-256.
17. Morgan T.O., Anderson A.I., MacInnis R.J.: ACE inhibitors, β-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am. J. Hypertens. 2001; 14: 241-247.
18. Neutel J.M.: Terapia skojarzona w nadciśnieniu tętniczym. Medycyna po Dyplomie 2009; 5: 1-52.
19. Morsico C., Lembo G., Sarno D. et al.: Benefit of combination therapy in hypertensive patients with associated coronary artery disease: a subgroup with specific demands. J. Cardiovasc. Pharmacol. 1998; 31(supl. 2): S27-33.
20. Messerli F.H., Weir M.R., Neutel J.M.: Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting. Am. J. Hypertens. 2002; 15(6): 550-6.
21. Neutel J.M., Smith D.H., Weber M.A.: Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. Am. J. Hypertens. 2004; 17(1): 37-42.
22. Jamerson K., Weber M.A., Bakris G.L. et al.: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417-2428.
2. Kearney P.M., Whelton M., Reynolds K. et al.: Worldwide prevalence of hypertension: a systematic review. J. Hypertens. 2004; 22: 11-19.
3. Wolf-Maier K., Cooper R.S., Banegas J.R. et al.: Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA 2003; 289: 2363-2369.
4. Strasser T.: Hypertension: the East European experience. Am. J. Hypertens. 1998; 11: 756-758.
5. Zdrojewski T., Bandosz P., Szpakowski P. et al.: Rozpowszechnienie głównych czynników ryzyka chorób układu sercowo-naczyniowego w Polsce. Wyniki badania NATPOL PLUS. Kardiol. Pol. 2004; 61(supl. 4): S1-S26.
6. Tykarski A., Posadzy-Małaczyńska A., Wyrzykowski B. et al.: Rozpowszechnienie nadciśnienia tętniczego oraz skuteczność jego leczenia u dorosłych mieszkańców naszego kraju. Wyniki programu WOBASZ. Kardiol. Pol. 2005; 63: S614-S619.
7. Mancia G., De Backer G., Dominiczak A. et al.: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Hypertension (ESH). J. Hypertens. 2007; 25: 1105-87.
8. Mancia G., Laurent S., Agabiti-Rosei E. et al.: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 2009; 27: 2121-58.
9. Widecka K., Grodzicki T., Narkiewicz K. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2011 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze 2011; 15: 55-82.
10. Kasprzak J.D.: Optymalna kontrola ciśnienia tętniczego u pacjentów z grupy wysokiego ryzyka krążeniowego: pozycja perindoprilu. Choroby Serca i Naczyń 2011; 2: 53-61.
11. Opie L.H.: Inhibitory konwertazy angiotensyny. Postęp trwa. Via Medica, Gdańsk 2000.
12. Schaller M., Nussberger J., Waeber B. et al.: Haemodynamic and pharmacological effects of the converting enzyme inhibitor benazepril HCl in normal volunteers. Eur. J. Clin. Pharmacol. 1985; 28: 267-272.
13. Johnston C.I., Mendelsohn F.A.O., Cubela R.B. et al.: Inhibition of angiotensin converting enzyme (ACE) in plasma and tissues: studies ex vivo after administration of ACE inhibitors. J. Hypertens. 1988; 6(supl. 3): S17-S22.
14. Smith W.M., Gomez H.J.: The use of benazepril in hypertensive patients age 55 and over. Clin. Cardiol. 1991; 14: 79-90.
15. Bellet M., Whalen J.J., Bodin F. et al.: Use of crossover trials to obtain antihypertensive dose-response curves and to study combination therapy during the development of benazepril. J. Hypertens. 1990; 8: 43-48.
16. Fogari R., Zoppi A., Lusardi P. et al.: Effects of benazepril alone and in combination with hydrochlorothiazide in comparison with felodypine extended release in elderly patients with mild-to-moderate essential hypertension. Curr. Therap. Res. 1998; 59: 246-256.
17. Morgan T.O., Anderson A.I., MacInnis R.J.: ACE inhibitors, β-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am. J. Hypertens. 2001; 14: 241-247.
18. Neutel J.M.: Terapia skojarzona w nadciśnieniu tętniczym. Medycyna po Dyplomie 2009; 5: 1-52.
19. Morsico C., Lembo G., Sarno D. et al.: Benefit of combination therapy in hypertensive patients with associated coronary artery disease: a subgroup with specific demands. J. Cardiovasc. Pharmacol. 1998; 31(supl. 2): S27-33.
20. Messerli F.H., Weir M.R., Neutel J.M.: Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting. Am. J. Hypertens. 2002; 15(6): 550-6.
21. Neutel J.M., Smith D.H., Weber M.A.: Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. Am. J. Hypertens. 2004; 17(1): 37-42.
22. Jamerson K., Weber M.A., Bakris G.L. et al.: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417-2428.